Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 4/20 | 0.50 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.50 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.44 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | KLK7 | P49862 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23606053 | 0.90 | KMT2A (0.41) | MTNR1AMTNR1BMEN1LMNAKMT2A | |
| SCHEMBL21991880 | 0.89 | ALDH1A1 (0.39) | MTNR1AMTNR1BHTTMEN1LMNA | |
| SCHEMBL21991550 | 0.89 | MTNR1A (0.45) | MTNR1AMTNR1BTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL21991868 | 0.89 | GAA (0.42) | MTNR1AMTNR1BKLK7KMT2A | |
| SCHEMBL21991885 | 0.89 | ALDH1A1 (0.43) | MTNR1AMTNR1BKLK7HTTMEN1 | |
| SCHEMBL21991869 | 0.87 | MTNR1A (0.48) | MTNR1AMTNR1BTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL21991879 | 0.87 | MTNR1A (0.43) | MTNR1AMTNR1BTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL21992677 | 0.86 | GAA (0.40) | MTNR1AMTNR1BKLK7 | |
| SCHEMBL21991905 | 0.86 | ALDH1A1 (0.39) | MTNR1AMTNR1BALDH1A1 | |
| SCHEMBL21992635 | 0.82 | MTNR1A (0.61) | MTNR1AMTNR1BTAS1R3TAS1R1TAS1R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220409566-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-12-29 | — | — | US | disclosed |
| US-20220142961-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-05-12 | — | — | US | disclosed |
| US-11318111-B2 | CCL5 inhibitors | LAPKO INC (US) | 2022-05-03 | — | — | US | disclosed |
| US-20210196665-A1 | CCL5 Inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-07-01 | — | — | US | disclosed |
| US-10940132-B2 | CCL5 inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200138766-A1 | CCL5 INHIBITORS | LAPKO INC. DBA AFECTA PHARMACEUTICALS | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220142961-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | MTNR1A 3190/4885MTNR1B 2158/4885TAS1R3 1961/4885 |
| US-20200138766-A1 | CCL5 INHIBITORS | CCL5, CCL11, CCR5 | MTNR1A 3190/4885MTNR1B 2158/4885TAS1R3 1961/4885 |
| US-20210196665-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | MTNR1A 3190/4885MTNR1B 2158/4885TAS1R3 1961/4885 |
| US-10940132-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | MTNR1A 3190/4885MTNR1B 2158/4885TAS1R3 1961/4885 |
| US-11318111-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | MTNR1A 3190/4885MTNR1B 2158/4885TAS1R3 1961/4885 |
| US-20220409566-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | MTNR1A 3190/4885MTNR1B 2158/4885TAS1R3 1961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.